Loading…

Inventiva SAIVA.PACompetitor analysis, valuation and peers

France · EUR·Health Care›Biotechnology
Momentum laggard 8
Mkt cap
$763M
US dollars, full cap
Free float
69%
of shares outstanding
$/day
$2.09M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
n/a
WACC 7.0%
Hurdle
n/a
no reverse DCF
Next earnings
133 days
31 Mar 2027
Close · EUR€2.91
1D+0.7%
1W-17.0%
1M+0.3%
3M-27.6%
6M-36.0%
YTD-26.2%
1Y-16.0%
ATR %8.6%
52w lowhigh53.1% off high

What Inventiva does

Employees: 77

Inventiva at a glance

Size Inventiva (IVA.PA) is a France Health Care company (Biotechnology) with a market value of $763M, the 152nd largest of 206 France companies the cockpit tracks. Shares closed at €2.91 on 18 Nov 2026.

Performance Over six months the shares fell 36.0%, against -12.2% for the median peer and -2.1% for the France market (cap-weighted) — 5th lowest of 19 in its peer set.

Growth Revenue fell 99.6% over the last twelve months (peer median +15.1%); the operating margin is -307,063.3% (peer median -84.7%).

Valuation It trades at 12,169.8× enterprise value to sales against a peer median of 6.6× (most expensive of 17).

Next results Next results expected around 31 Mar 2027 (exchange calendar; dates can move).

Relative performance

608010021 May 202621 Aug 202618 Nov 2026Peer median 89IVA.PA 64
Six months, rebased to 100: Inventiva against the median of its 20 peers (local-currency closes).

Inventiva financials

Reported figures in EUR; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue€49,000€4.48M€9.20M€17.5M€12.2M
Revenue growth—-51%-47%+44%—
Gross profit-€2.56M€1.57M€5.61M€14.9Mn/a
EBITDA-€148M-€133M-€95.9M-€105M-€61.0M
Net income-€248M-€354M-€184M-€110M-€54.3M
Free cash flow-€110M-€105M-€86.3M-€82.2M-€45.5M
Capital expenditure€358,000€247,000€333,000€540,000€561,000
Total debtn/a€59.4M€54.3M€37.4M€34.5M

Quarterly statements and history in the cockpit →

Inventiva competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+500%+1,000%-25%0%+25%+50%9887SNDXGLUE688526AURA002038MGTXATTOSLDB77294587IVA.PA6-month return →1-month return →
Up and to the right = strong over both horizons. Inventiva is the large dot.

Fundamentals: revenue growth against valuation

0%+500%+1,000%0×5,000×10,000×SNDXGLUE688526APMDMGTXVSTMIVA.PARevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Inventiva is the large dot.

Inventiva competitors and peer comparison

How Inventiva compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Inventiva against its 20 peers (data as of 18 Nov 2026)
MeasureIVA.PAPeer medianRank in peer set
1-month return+0.3%-6.9%7th highest of 21
6-month return-36.0%-12.2%5th lowest of 19
Distance from 52-week high-53.1%-44.9%6th lowest of 21
Revenue growth (TTM)-99.6%+15.1%lowest of 15
Operating margin-307,063.3%-84.7%lowest of 17
EV / Sales12,169.8×6.6×most expensive of 17

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Inventiva IVA.PAFrance$763M-36%-100%-307,063%12,169.8×n/an/a
Nanjing Leads Biolabs 9887.HKHong Kong$764M-50%n/a-108%21.1×n/an/a
Syndax Pharmaceuticals SNDXUnited States$771M-57%+160%-62%3.2×n/an/a
Monte Rosa Therapeutics GLUEUnited States$775M-51%-61%-214%3.3×n/an/a
Wuhan Keqian Biology 688526.SSChina$780M-24%-22%20%4.4×7.8%+2.4%
Aura Biosciences AURAUnited States$743M-4%n/an/an/an/an/a
Beijing SL Pharmaceutical 002038.SZChina$736M-20%-4%-119%6.9×-13.5%-10.9%
Apnimed APMDUnited States$726Mn/a+380%-140%10.8×n/an/a
R&G PharmaStudies 301333.SZChina$722M-11%+21%11%3.4×17.3%+11.8%
MeiraGTx MGTXUnited States$813M-13%+1,366%44%1.9×n/an/a
Shaanxi Micot Pharmaceutical Technology 2335.HKHong Kong$715Mn/an/an/an/an/an/a
Attovia Therapeutics ATTOUnited States$710M+1,325%n/a-5,945%220.7×n/an/a
Solid Biosciences SLDBUnited States$709M-2%n/an/an/an/an/a
Prime Medicine PRMEUnited States$695M+35%+18%-2,584%105.4×n/an/a
Oxford BioMedica OXB.LUnited Kingdom$841M-15%+16%-18%4.1×n/an/a
Anhui Wanbang Pharmaceutical Technology 301520.SZChina$684M+74%-15%-8%14.7×44.8%+14.7%
Kura Oncology KURAUnited States$674M-29%-24%-394%2.6×n/an/a
Verastem VSTMUnited States$866M+66%+650%-194%8.2×n/an/a
Steminent Biotherapeutics 7729.TWOTaiwan$668M+292%n/an/an/an/an/a
Alphamab Oncology 9966.HKHong Kong$666M-38%-32%-38%6.7×n/an/a
Peptidream 4587.TJapan$878M-3%+14%-18%6.6×n/an/a

Questions

Which companies are Inventiva's closest peers?
The cockpit's peer set: Nanjing Leads Biolabs (9887.HK), Syndax Pharmaceuticals (SNDX), Monte Rosa Therapeutics (GLUE), Wuhan Keqian Biology (688526.SS), Aura Biosciences (AURA), Beijing SL Pharmaceutical (002038.SZ), Apnimed (APMD), R&G PharmaStudies (301333.SZ).
Is Inventiva expensive compared with its peers?
On ev / sales it trades at 12,169.8× against a peer median of 6.6×, most expensive of 17 in its peer set.
How has Inventiva stock performed?
Over six months to 18 Nov 2026 the shares returned -36.0% against -12.2% for the median peer; over one year -16.0%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.